Table 4.

Summary of multivariate analysis of outcome of the 2 lung adenocarcinoma patients' cohorts by combined expression of EZH2Low/TTF-1High versus other groups

Cohort 1 (n = 320)Cohort 2 (n = 91)
FeaturesCategoriesP valueHR (95% CI)Overall PaP valueHR (95% CI)Overall Pa
Overall survival analysis
 EZH2/TTF-1EZH2Low/TTF-1High vs. Others0.00110.45 (0.278–0.726)0.04660.221 (0.050–0.971)
 AgeMedian (66.3 yrs)<0.00012.058 (1.455–2.913)0.62880.814 (0.354–1.873)
 SexMale vs. Female0.13191.300 (0.924–1.828)0.04782.226 (1.008–4.919)
 Tumor sizeMedian (2.7 cm)0.02171.502 (1.061–2.126)0.22131.672 (0.734–3.812)
 TNM stageIII vs. I<0.00013.621 (2.166–6.054)<0.00010.00164.768 (1.805–12.596)0.0068
II vs. I0.01221.681 (1.120–2.523)0.18341.825 (0.752–4.426)
 Adjuvant therapyYes vs. No0.00970.549 (0.348–0.865)0.31970.692 (0.252–1.568)
Recurrence-free survival analysis
 EZH2/TTF-1EZH2Low/TTF-1High vs. Others0.00870.51 (0.309–0.844)0.06940.362 (0.121–1.084)
 Tumor sizeMedian (2.7 cm)0.06391.435 (0.979–2.103)0.12411.915 (0.837–4.384)
 TNM stageIII vs. I<0.00014.671 (2.734–7.982)<0.00010.04932.641 (1.003–6.954)0.1445
II vs. I0.00112.110 (1.349–3.300)0.76781.151 (0.452–2.932)
 Adjuvant therapyYes vs. No0.29570.788 (0.505–1.231)0.40470.678 (0.272–1.690)
  • aP value for overall effect.